

18 September 2024

**Scancell Holdings plc**  
("Scancell" or the "Company")

**Notice of Final Results**

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, will announce its results for the year ended 30 April 2024 on Tuesday 24 September 2024.

Professor Lindy Durrant, Chief Executive Officer, and Sath Nirmalanathan, Chief Financial Officer, will host a virtual analyst briefing at 13:00 BST on the day of the results. There will also be a live webcast and conference call with a Q&A session. The webcast will be shared on the Investor Relations section of the Company's website at <https://scancell.co.uk/>.

**-ENDS-**

**For further information, please contact:**

<b>Scancell Holdings plc</b>	+44 (0) 20 3709 5700
Dr Jean-Michel Cosséry, Non-Executive Chairman	
Professor Lindy Durrant, CEO	
<b>Panmure Liberum Limited</b> (Nominated Advisor and Joint Broker)	+44 (0) 20 7886 2500
Emma Earl, Freddy Crossley, Will Goode, Mark Rogers (Corporate Finance)	
Rupert Dearden (Corporate Broking)	+44 (0) 20 3705 9330
<b>WG Partners LLP</b> (Joint Broker)	
David Wilson/Claes Spang/Satheesh Nadarajah/Erland Sternby	
<b>ICR Consilium</b>	+44 (0) 20 3709 5700
Mary-Jane Elliott/Angela Gray/Lindsey Neville	<a href="mailto:scancell@consilium-comms.com">scancell@consilium-comms.com</a>

**About Scancell**

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's approaches are that vaccines (ImmunoBody® and Moditope®) use unique receptors to target antigens to activated antigen presenting cells whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>

information, please contact [rns@seg.com](mailto:rns@seg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORBCGDCCDBDGSR